Why Is Oxford Biomedica plc Up Today?
Oxford Biomedica plc shares rose 1.97% today, based on the supplied market data. The move comes amid ongoing corporate activity, including a confirmed unsolicited cash offer from funds managed by EQT for the entire company, alongside continued strong underlying operational execution.
The company's 2025 preliminary results, announced in March 2026, showed 33% constant-currency Revenue growth and a return to Operating EBITDA profitability, delivering on its pure-play CDMO strategy.
Strong commercial Demand for cell and gene therapy Manufacturing services appears to be underpinning both the operational momentum and the strategic interest in the company.
About Oxford Biomedica plc
Oxford Biomedica (OXB) is a global quality and innovation-led cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), providing viral vector manufacturing services to pharmaceutical and biotech clients.
Following a strategic transformation completed on 1 January 2024, the company operates as a pure-play CDMO, having exited its own Drug Development pipeline to focus entirely on manufacturing services for clients across the cell and gene therapy sector.
For LSE:OXB, the most important indicators are total revenue growth, contracted value of client orders, Operating EBITDA margin, GMP suite utilisation, and the number of late-stage and commercial client programmes supported.
Key Reasons Behind Today's Uptick
2025 preliminary results showed the company achieved 33% constant-currency revenue growth and Operating EBITDA profitability, a significant milestone following the pure-play CDMO transformation, with medium-term guidance targeting revenues of £220-240 million for 2026.
The contracted value of client orders reached £224 million for the year ended 31 December 2025, an increase of 20% compared with the prior year, reflecting increasing demand for OXB's manufacturing services.
The company made targeted investments to expand capacity, including the Acquisition of an FDA-approved, commercial-scale viral vector manufacturing Facility in Durham, North Carolina, enhancing its late-stage and commercial AAV manufacturing capabilities.
A Confirmed Takeover Approach From EQT
Oxford Biomedica has confirmed receiving an unsolicited cash offer from funds managed by EQT for all of its shares, a development that has introduced significant corporate activity into the Investment case alongside the underlying operational story.
Deutsche Bank subsequently upgraded the stock to Buy from Hold with a substantially raised price target, citing a higher-quality Business following the company's operational improvements and strategic clarity as a pure-play CDMO.
The combination of strong fundamental momentum and takeover interest has introduced both upside potential and uncertainty into how the situation ultimately resolves for shareholders.
Growth Catalysts
Continued growth in the contracted value of client orders, already up 20% year-on-year, provides visibility into future revenue and suggests further growth ahead as GMP suite utilisation increases.
Medium-term guidance for 25-30% revenue growth in FY27-28 and rising EBITDA margins toward at least 20% in FY2027, with longer-term potential approaching 30% over five to six years, points to a substantial Margin expansion opportunity if delivered.
The Durham, North Carolina facility acquisition expands OXB's commercial-scale manufacturing capacity, particularly in AAV vectors, positioning the company to support a growing number of clients preparing for commercial launch.
Key Risks
Revenue forecast risk has been demonstrated previously, with the stock having fallen sharply on a prior occasion after the company cut its annual revenue forecast citing operational delays at a US site and deferred client orders.
The confirmed EQT takeover approach introduces binary outcome risk for shareholders, with the ultimate resolution of the offer process potentially having a significant impact on the share price in either direction.
As a CDMO dependent on client programme success, OXB's revenue visibility can be affected by delays or discontinuations in client clinical trials, particularly for early-stage programmes.
The cell and gene therapy CDMO market is competitive, with several well-capitalised players competing for capacity reservations from pharmaceutical and biotech clients.
Valuation
Oxford Biomedica can be valued using enterprise-value-to-revenue and forward EBITDA multiples typical of specialty CDMO businesses, alongside its contracted order Backlog as an indicator of near-term revenue visibility.
Investors should weigh the strong underlying operational momentum and margin expansion trajectory against both the near-term revenue Volatility the company has shown historically and the uncertainty introduced by the EQT approach.
The scale of any potential takeover premium, relative to the company's standalone valuation based on its medium-term growth and margin targets, will be a key consideration for shareholders evaluating the situation.
What Investors Should Watch Next
Investors should watch for further developments and updates regarding the EQT takeover approach, including any formal offer terms or Board recommendation.
Progress toward the FY2026 revenue guidance of £220-240 million and continued growth in contracted client order value will remain important operational indicators.
Capacity utilisation at the Durham, North Carolina facility and the number of late-stage client programmes preparing for commercial launch should also be monitored.






Please wait processing your request...